Novartis AG to Discuss Kesimpta® FDA Approval Investor Call Transcript
Good morning and good afternoon, and welcome to the Kesimpta FDA Approval Investor Call. (Operator Instructions) And the conference is being recorded. (Operator Instructions) A recording of the conference, including the Q&A session, are available on our website shortly after the call ends. (Operator Instructions)
With that, I would like to hand over to Samir Shah, Global Head, Investor Relations. Please go ahead, sir.
Thank you very much, and good morning and good afternoon, everybody. Welcome to the Kesimpta approval call. First of all, I'd like to say a big thank you for taking the time to participate on a Friday afternoon. We appreciate you're busy, and we appreciate the time that you're actually taking to listen to the presentation. We hope the presentation's of interest to you and we can clarify any of the outstanding issues or questions that you may have.
With us on the call, we have Marie-France Tschudin. She, as you know, is the Head of the Pharmaceutical division for Novartis. We also
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
